Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bazedoxifene (Wyeth).

Literature DB >> 15535430

Bazedoxifene (Wyeth).

Abstract

Bazedoxifene is a tissue-specific selective estrogen receptor modulator being developed by Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories) to be used alone for the prevention and treatment of osteoporosis in postmenopausal women and in combination with Premarin for menopausal symptoms. As of March and June 2004, worldwide phase III trials for bazedoxifene, and bazedoxifene in combination with Premarin, were ongoing.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15535430

Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472

Keyword Cloud
Cited

14 in total

1. Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice.

Authors: Jun Ho Kim; Matthew S Meyers; Saja S Khuder; Simon L Abdallah; Harrison T Muturi; Lucia Russo; Chandra R Tate; Andrea L Hevener; Sonia M Najjar; Corinne Leloup; Franck Mauvais-Jarvis
Journal: Mol Metab Date: 2014-01-09 Impact factor: 7.422

2. Bazedoxifene: literature data and clinical evidence.

Authors: Stefano Lello; Maria Luisa Brandi; Giovanni Minisola; Salvatore Minisola; Andrea Riccardo Genazzani
Journal: Clin Cases Miner Bone Metab Date: 2011-09

Review 3. Osteoporosis prevention and therapy: preserving and building strength through bone quality.

Authors: M Kleerekoper
Journal: Osteoporos Int Date: 2006-08-15 Impact factor: 4.507

4. Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.

Authors: Yangfan Zheng; Manghong Zhu; Sathish Srinivasan; Jerome C Nwachukwu; Valerie Cavett; Jian Min; Kathryn E Carlson; Pengcheng Wang; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal: ChemMedChem Date: 2012-04-19 Impact factor: 3.466

5. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Authors: Patrick M Kelly; Niall O Keely; Sandra A Bright; Bassem Yassin; Gloria Ana; Darren Fayne; Daniela M Zisterer; Mary J Meegan
Journal: Molecules Date: 2017-08-31 Impact factor: 4.411

Bazedoxifene (Wyeth).

1. Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice.

2. Bazedoxifene: literature data and clinical evidence.

Review 3. Osteoporosis prevention and therapy: preserving and building strength through bone quality.

4. Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.

5. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Review 6. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.

Review 7. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis.

Review 8. Update on bazedoxifene: a novel selective estrogen receptor modulator.

9. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

Review 10. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.